BLU-667 (Pralsetinib)
98%
- Product Code: 107854
CAS:
2097132-94-8
| Molecular Weight: | 533.60 g./mol | Molecular Formula: | C₂₇H₃₂FN₉O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
BLU-667, also known as Pralsetinib, is primarily used in the treatment of certain types of cancer. It is specifically effective in targeting cancers caused by RET gene alterations, which include non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers. The drug works by inhibiting the activity of the RET protein, which is crucial for the growth and survival of cancer cells with these mutations. This targeted approach helps to slow down or stop the progression of the disease, offering a more precise treatment option compared to traditional chemotherapy. Pralsetinib is particularly beneficial for patients who have developed resistance to other treatments or who have specific genetic mutations that make them suitable candidates for this therapy. Its use is typically guided by genetic testing to ensure it is prescribed to those who are most likely to benefit.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Off-White Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.010 | 10-20 days | ฿12,280.00 |
+
-
|
BLU-667 (Pralsetinib)
BLU-667, also known as Pralsetinib, is primarily used in the treatment of certain types of cancer. It is specifically effective in targeting cancers caused by RET gene alterations, which include non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers. The drug works by inhibiting the activity of the RET protein, which is crucial for the growth and survival of cancer cells with these mutations. This targeted approach helps to slow down or stop the progression of the disease, offering a more precise treatment option compared to traditional chemotherapy. Pralsetinib is particularly beneficial for patients who have developed resistance to other treatments or who have specific genetic mutations that make them suitable candidates for this therapy. Its use is typically guided by genetic testing to ensure it is prescribed to those who are most likely to benefit.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :